Australia markets close in 1 hour 19 minutes

Addex Therapeutics Ltd (ADXN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.83+0.10 (+1.08%)
At close: 11:07AM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 571.35M
Enterprise value 331.17M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)18.54
Price/book (mrq)2.69
Enterprise value/revenue 38.10
Enterprise value/EBITDA 7-2.79

Trading information

Stock price history

Beta (5Y monthly) 1.42
52-week change 3-15.46%
S&P500 52-week change 331.83%
52-week high 337.52
52-week low 38.88
50-day moving average 39.80
200-day moving average 310.43

Share statistics

Avg vol (3-month) 35.54k
Avg vol (10-day) 32.55k
Shares outstanding 57.26M
Implied shares outstanding 6N/A
Float 3.35M
% held by insiders 10.00%
% held by institutions 13.86%
Shares short (14 July 2021) 42.3k
Short ratio (14 July 2021) 40.33
Short % of float (14 July 2021) 4N/A
Short % of shares outstanding (14 July 2021) 40.04%
Shares short (prior month 14 June 2021) 44.95k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CHF.

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Mar 2021


Profit margin -290.78%
Operating margin (ttm)-288.86%

Management effectiveness

Return on assets (ttm)-24.93%
Return on equity (ttm)-52.69%

Income statement

Revenue (ttm)3.85M
Revenue per share (ttm)0.81
Quarterly revenue growth (yoy)-3.20%
Gross profit (ttm)-6.47M
EBITDA -11.19M
Net income avi to common (ttm)-11.19M
Diluted EPS (ttm)-2.61
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)25.23M
Total cash per share (mrq)4.45
Total debt (mrq)489.8k
Total debt/equity (mrq)2.37
Current ratio (mrq)5.70
Book value per share (mrq)3.65

Cash flow statement

Operating cash flow (ttm)-10.79M
Levered free cash flow (ttm)-6.2M